Myeloproliferative Disorders

Myeloproliferative disorders are a group of clonal haematological neoplasms characterised by proliferation of one or more cells of myeloid lineage. They are the result of acquired mutations in the progenitor cell leading to hyper proliferation or neoplastic expansion of more mature forms of myeloid cells. Cells retain their functional ability with some degree of defects and also lead to suppression of normal stem cells. The most common type of Myeloproliferative Neoplasms (MPN) can broadly be classified into BCR ABL positive (Chronic Myelogenous Leukemia) and BCR ABL negative Disorders (Polycythemia Vera PV, Essential Thrombocytosis ET and Primary Myelofibrosis PMF). There are other rare types which have relatively low incidence like chronic neutrophilic leukemia, chronic eosinophilic leukemia, systemic mastocytosis and myeloproliferative neoplasms unclassifiable. These are the indolent type of haematological malignancies associated with marrow hypercellularity and organomegaly, with gradual progression to myelofibrosis or transformation to acute leukemias. During the dormant course of the BCR ABL negative MPN, they are more prone to thrombo-hemorrhagic complications and the treatment strategy is directed mostly to prevent complications. The past decade; therapies for BCR ABL positive disease (CML) have been a milestone achievement in keeping the disease in remission for many years, preventing major complications and halting the progression of the disease. This book discusses the classification, diagnosis and treatment of myeloproliferative diseases and provides insight on the symptoms and risk factors involved in the diseases.

Presentation of the myeloproliferative neoplasms (MPNs) varies widely, and correct diagnosis and management can be challenging, and is becoming more complex as understanding of the underlying molecular basis for these disorders emerges. Appropriate management is increasingly informed by accurate risk stratification founded on understanding of cytogenetic and molecular markers, as well as the clinical presentation. 'Fast Facts: myeloproliferative neoplasms' focuses on the three most common chronic MPNs: • Essential thrombocythemia (ET) – characterized by increased platelet count • Polycythemia vera (PV) – characterized by excessive production of red blood cells • Primary myelofibrosis – a more severe and heterogenous disorder that may overlap with ET and PV but is commonly associated with anemia. Written by two leading experts in the field, Fast Facts: myeloproliferative neoplasms provides concise, up-to-date and practical guidance on the accurate diagnosis, risk stratification and management of these MPNs. It also provides key insights into our growing understanding of the underlying molecular and genetic basis of these disorders, and how this is informing risk stratification and management strategies. This concise handbook will be invaluable to clinicians, medical students, nurses, pharmacists and scientists in understanding and overcoming the everyday and rarer challenges associated with MPN.

This book contains a series of contributions from internationally renowned academics with special expertise in one or other diseases which collectively are grouped under the heading myeloproliferative disorders. There have been many recent developments in understanding the pathophysiology and a number therapeutic innovations in this area. A feature of this book is the speed with which it has been produced – an important factor in this rapidly moving field.

This is a concise, practical, case-based book documenting examples and scenarios that will help you manage challenging clinical issues for patients with myeloproliferative neoplasms. The editors and authors have strived to distil the very latest information in this rapidly advancing field in a way that will help you to update your practice and manage your patients. The key focuses are: diagnosis, both standard and challenging; both day-to-day management as well as special situations such as surgery, thrombotic events and pregnancy; and finally, managing evolving situations with MPN such as progression to acute myeloid leukemia. This book is an outstanding resource that includes a discussion of both classical myeloproliferative neoplasms, such as essential thrombocythemia, polycythemia vera and myelofibrosis, and also less common disorders such as systemic mast cell disease, hypereosinophilia, MPN/MBS overlap syndromes and atypical CML, amongst others. This book is a practical reference for practitioners, hematologists, medical oncologists and trainees.

This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic approaches, the value and limitations of mutation screening for diagnostic and prognostic purposes, risk stratification in terms of both survival and other disease complications such as leukemic transformation and thrombosis, and modern therapeutic strategies, including conventional drugs, allogeneic stem cell transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.

With the recent discovery of JAK2 mutations in myeloproliferative disorders, medical science has taken a revolutionary stride forward toward understanding the pathogenesis of these diseases. This new advancement translates not only to a more rapid and reliable diagnosis, but also allows groundbreaking research into the development of new therapeuti

With the new classification of chronic myeloproliferative disorders, and the rise of interest in molecularly targeted therapies, this timely text brings together international experts on the topic to discuss the current technologies and their implications for the treatment of patients. This title comprehensively covers chronic myeloid leukemia and Ph-negative chronic myeloproliferative disorders and is an essential resource for all practitioners in Hematologic Oncology.

This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic approaches, the value and limitations of mutation screening for diagnostic and prognostic purposes, risk stratification in terms of both survival and other disease complications such as leukemic transformation and thrombosis, and modern therapeutic strategies, including conventional drugs, allogeneic stem cell transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.